Reviva Pharmaceuticals, which is developing a drug to treat schizophrenia, disclosed on Thursday that it has raised $12 million in debt and equity funding. The San Jose company led by CEO Laxminarayan Bhat didn’t disclose its funders but said the money came from 82 people. Bhat is the only person listed on the Securities & Exchange Commission filing about the funding.